Ashley Hume is a healthcare executive with more than 25 years of experience developing and leading innovative reimbursement, cost-containment, and risk-management strategies. As Chief Executive Officer of Emerging Therapy Solutions® (ETS), Ashley has led the development and national expansion of the company’s cell and gene therapy and transplant solutions, supporting health plans, self-funded employers, third-party administrators, and reinsurers as they navigate the clinical and financial complexities associated with high-cost therapies.

Ashley is actively engaged in national discussions surrounding cell and gene therapy reimbursement, payment models, access, and financial risk. Throughout her career, she has held leadership roles across health plans, health-plan services organizations, specialty medical groups, and health systems, giving her a broad perspective on the payer, provider, and patient dynamics that shape healthcare delivery.